Immunotherapy with hymenoptera venom in a child with anaphylaxis

Detalhes bibliográficos
Autor(a) principal: Falcão, Inês
Data de Publicação: 2021
Outros Autores: Cunha, Leonor
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://doi.org/10.25753/BirthGrowthMJ.v30.i2.19718
Resumo: Systemic reactions to hymenoptera venom in childhood are uncommon, comprising less than 1% of cases. The prevalence proves higher in adults, encompassing 0.3−8.9%. Anaphylaxis forms the most severe of all allergic reactions and can be fatal. Specific immunotherapy based on hymenoptera venom is the only treatment that prevents moderate-to-severe systemic reactions. Due to immunotherapy safety and effectiveness, this treatment is indicated during childhood in cases of grade II and III systemic reactions. The authors describe the clinical case of a fourteen-year-old male patient, son of a beekeeper, who was followed in the Allergy and Clinical Immunology Department due to anaphylaxis to hymenoptera venom and was under immunotherapy to Apis mellifera venom since the age of nine, besides complying with measures to evade hymenoptera.
id RCAP_f8361dbf893dbe4cad3db79d581bb291
oai_identifier_str oai:ojs.revistas.rcaap.pt:article/19718
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Immunotherapy with hymenoptera venom in a child with anaphylaxisImunoterapia com veneno de himen pteros numa criança com anafilaxiaCase ReportsSystemic reactions to hymenoptera venom in childhood are uncommon, comprising less than 1% of cases. The prevalence proves higher in adults, encompassing 0.3−8.9%. Anaphylaxis forms the most severe of all allergic reactions and can be fatal. Specific immunotherapy based on hymenoptera venom is the only treatment that prevents moderate-to-severe systemic reactions. Due to immunotherapy safety and effectiveness, this treatment is indicated during childhood in cases of grade II and III systemic reactions. The authors describe the clinical case of a fourteen-year-old male patient, son of a beekeeper, who was followed in the Allergy and Clinical Immunology Department due to anaphylaxis to hymenoptera venom and was under immunotherapy to Apis mellifera venom since the age of nine, besides complying with measures to evade hymenoptera.As reações sistémicas a veneno de himenópteros na infância são incomuns, atingindo menos de 1% dos casos. Em adultos, essa prevalência é mais elevada, podendo ser de 0,3 a 8,9%. A anafilaxia é a reação alérgica mais grave, podendo ser fatal. A imunoterapia específica com veneno de himenópteros é o único tratamento que previne reações sistémicas moderadas a graves. A segurança e eficácia da imunoterapia fazem com que este tratamento esteja indicado em casos de reação sistémica de grau II e III em idade pediátrica. Os autores descrevem o caso clínico de um doente de 14 anos, do sexo masculino, filho de um apicultor, seguido na consulta de Imunoalergologia por anafilaxia a veneno de himenóptero e sob imunoterapia a veneno de Apis mellifera desde os nove anos de idade, para além de cumprir medidas de evicção a himenópteros.Centro Hospitalar Universitário do Porto2021-06-30T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttps://doi.org/10.25753/BirthGrowthMJ.v30.i2.19718eng2183-9417Falcão, InêsCunha, Leonorinfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2022-09-21T14:55:39Zoai:ojs.revistas.rcaap.pt:article/19718Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T15:56:31.608792Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Immunotherapy with hymenoptera venom in a child with anaphylaxis
Imunoterapia com veneno de himen pteros numa criança com anafilaxia
title Immunotherapy with hymenoptera venom in a child with anaphylaxis
spellingShingle Immunotherapy with hymenoptera venom in a child with anaphylaxis
Falcão, Inês
Case Reports
title_short Immunotherapy with hymenoptera venom in a child with anaphylaxis
title_full Immunotherapy with hymenoptera venom in a child with anaphylaxis
title_fullStr Immunotherapy with hymenoptera venom in a child with anaphylaxis
title_full_unstemmed Immunotherapy with hymenoptera venom in a child with anaphylaxis
title_sort Immunotherapy with hymenoptera venom in a child with anaphylaxis
author Falcão, Inês
author_facet Falcão, Inês
Cunha, Leonor
author_role author
author2 Cunha, Leonor
author2_role author
dc.contributor.author.fl_str_mv Falcão, Inês
Cunha, Leonor
dc.subject.por.fl_str_mv Case Reports
topic Case Reports
description Systemic reactions to hymenoptera venom in childhood are uncommon, comprising less than 1% of cases. The prevalence proves higher in adults, encompassing 0.3−8.9%. Anaphylaxis forms the most severe of all allergic reactions and can be fatal. Specific immunotherapy based on hymenoptera venom is the only treatment that prevents moderate-to-severe systemic reactions. Due to immunotherapy safety and effectiveness, this treatment is indicated during childhood in cases of grade II and III systemic reactions. The authors describe the clinical case of a fourteen-year-old male patient, son of a beekeeper, who was followed in the Allergy and Clinical Immunology Department due to anaphylaxis to hymenoptera venom and was under immunotherapy to Apis mellifera venom since the age of nine, besides complying with measures to evade hymenoptera.
publishDate 2021
dc.date.none.fl_str_mv 2021-06-30T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://doi.org/10.25753/BirthGrowthMJ.v30.i2.19718
url https://doi.org/10.25753/BirthGrowthMJ.v30.i2.19718
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 2183-9417
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Centro Hospitalar Universitário do Porto
publisher.none.fl_str_mv Centro Hospitalar Universitário do Porto
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799130433373339648

Registros relacionados